SAN ANTONIO TX DEC 4, 2013.
America Stem Cell, Inc. (ASC) today announced that three presentations will be made at the upcoming American Society of Hematology (ASH) meeting in New Orleans, LA December 7-10, 2013 on its lead product, ASC-101. ASC-101 is currently undergoing evaluation in a dual umbilical cord blood transplantation study evaluating ASC-101 in patients with hematologic malignancies and myelodysplastic syndrome at The University of Texas MD Anderson Cancer Center. To date, 16 patients have been transplanted with cord blood that was treated with ASC-101 immediately prior to transplant. On the basis of interim data, ASC received clearance from the U.S. Food and Drug Administration (FDA) to begin a nationwide, Ph2 multicenter study.
The interim results from this study will be presented at the ASH meeting by Dr. Elizabeth Shpall, M.D., Medical Director, Cell Therapy Laboratory and Director, Cord Blood Bank at MD Anderson Cancer Center and Study Chair on both the ASC-101 Phase 1/2a clinical trial and the Ph2 multicenter trial. Dr. Shpall will give an oral presentation on Monday, December 9; the editors of the journal Blood have selected her talk as one of the top abstracts to be presented at ASH. In addition, an oral presentation on preclinical studies of the effects of ASC-101 treatment on cord blood engraftment, and a poster on the use of ASC-101 with natural killer cells, will be presented.
“We are pleased that Dr. Shpall’s study has had such positive results. The recognition by the ASH organizers to select her research for oral presentation demonstrates the importance of the study and, we believe, the potential of ASC-101 improving stem cell transplants in patients with hematological malignancies. ASC is dedicated to the development and commercialization of platform technologies that enable and expand the therapeutic potential of a wide variety of cell therapies with the aim of improving patient outcomes,” said Lynnet Koh, CEO of ASC.
The three abstracts to be presented are:
Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment
Popat et al. (Dr. Shpall will give an oral presentation)
Session: 711. Cell Collection and Processing I Abstract #691
Monday, December 9, 2013: 4:30 PM CST at Riverside Rooms – R02-R03 (Ernest N. Morial
Cord Blood CD34+ Stem Cell Sialyl Lewis X Levels and E-Selectin Binding Are
Predictive Of Engraftment In Mice: Functional Separation Of Stemness and Homing To
Zweidler-McKay et al. Session: 701. Experimental Transplantation:
Basic Biology, Engraftment and Disease Activity: Hematopoiesis, Homing and Experimental
Transplantation Tuesday, December 10, 2013: 8:30 AM Abstract #893
Room 388-390 (Ernest N. Morial Convention Center)
Forced Fucosylation With ASC-101 Enhances The Binding Of Ex Vivo Expanded Human
NK Cells To E-Selectin: A Novel Method To Improve The Homing Of Adoptively
Transferred NK Cells To The Bone Marrow In Patients With Hematological Malignancies
Onishi et al. Session: 703. Adoptive Immunotherapy: Poster III Abstract #4499
Monday, December 9, 2013, 6:00 PM-8:00 PM
Hall G (Ernest N. Morial Convention Center)